BEAM Alliance released position paper on PUSH incentives
BEAM Alliance has released a new position paper on PUSH Incentives called ‘Supporting financial investments on R&D to de-risk antimicrobial development”.
- Antimicrobial resistance (AMR) is a global, multi-sectoral issue that affects all countries and, if unaddressed, will become one of the most formidable health crises of the century
- Market failures and limited guidelines heavily impact the risk level associated with AMR R&D
- Currently, SMEs are by far the largest contributors to the AMR drug pipeline. SMEs are not cash flow positive and compete with other indication fields to capture equity and non-dilutive funding
- Funding instruments dedicated to the AMR community should be designed, in particular to move forward preclinical and clinical products, as a European complement to the CARB-X and BARDA initiatives
- The upcoming Horizon Europe framework programme offers various opportunities to set-up such targeted instruments